Zydus receives final approval from the USFDA for Sucralfate Tablets USP, 1 gram

Zydus Lifesciences Limited (including its subsidiaries/affiliates, hereafter referred to as "Zydus") has received final approval from the United States Food and Drug Administration (USFDA) to manufacture and market Sucralfate Tablets USP, 1 gram (USRLD: Carafate Tablets, 1 gram).

Sucralfate is used to treat and prevent ulcers in the intestines by forming a coating over ulcers, protecting the area from further injury. This helps ulcers heal more quickly. The drug will be manufactured at the group's topical manufacturing facility at SEZ, Ahmedabad (India).

Sucralfate Tablets USP, 1 gram had annual sales of USD 84 mn in the United States (IQVIA MAT Feb. 2023).

The group now has 367 approvals and has so far filed over 440* ANDAs since the commencement of the filing process in FY 2003-04.

Shares of Zydus Lifesciences Limited was last trading in BSE at Rs. 516.40 as compared to the previous close of Rs. 519.90. The total number of shares traded during the day was 18602 in over 764 trades.

The stock hit an intraday high of Rs. 524.00 and intraday low of 515.20. The net turnover during the day was Rs. 9660900.00.

(*as of 31st December 2022)

Source : Equity Bulls

Keywords

ZydusLifesciences INE010B01027 FinalApproval USFDA SucralfateTabletsUSP